Researchers from Stanford University found that drugs originally developed for cancer treatment, known as IDO1 inhibitors, could restore memory function and improve brain metabolism in preclinical trials, according to a new study published in the journal Science.
This class of drugs “wake up immune cells in cancer” and restore glucose metabolism in the brain by targeting a process known as the kynurenine pathway, Katrin Andreasson, the study’s senior author and a professor of neurology and neurological sciences at Stanford University School of Medicine, told The Epoch Times.
